An analysis of racial disparities in systemic treatments for psoriasis and their pharmacologic consequences
Archives of Clinical Toxicology · 2025
DOI: 10.46439/toxicology.7.038 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Clinical Toxicology, 2025. Verfasst von Rini Manoj Desai und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Psoriasis is a systemic inflammatory skin disease associated with significant comorbidities, yet access to effective systemic treatments remains disparate across racial and ethnic groups. Building upon recent findings of disparities in systemic medication prescriptions and hospitalization outcomes among patients with psoriasis, this commentary explores the pharmacologic, toxicologic, and health equity implications of these inequities. We discuss how prolonged undertreatment in marginalized populations exacerbates systemic inflammation, increases disease burden, and perpetuates poor health outcomes. Addressing these disparities requires a comprehensive, multidisciplinary approach aimed at ensuring all patients with psoriasis can benefit from advances in systemic therapies.
Zitieren
APA
Desai, R. M., McCune, M., Olsen, R., Tong, L., & Davis, M. S. (2025). An analysis of racial disparities in systemic treatments for psoriasis and their pharmacologic consequences. Archives of Clinical Toxicology. https://doi.org/10.46439/toxicology.7.038
Vancouver
Desai RM, McCune M, Olsen R, Tong L, Davis MS. An analysis of racial disparities in systemic treatments for psoriasis and their pharmacologic consequences. Archives of Clinical Toxicology. 2025. doi:10.46439/toxicology.7.038
BibTeX
@article{Desai2025,
author = {Desai, Rini Manoj and McCune, Mariana and Olsen, Rebecca and Tong, Liliana and Davis, Mitchell Sparling},
title = {An analysis of racial disparities in systemic treatments for psoriasis and their pharmacologic consequences},
journal = {Archives of Clinical Toxicology},
year = {2025},
doi = {10.46439/toxicology.7.038}
}
EUVIMED